Promote a Clinical Trial

First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)

The goal of this clinical research study is to learn if the combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab can help control CLL. The safety of this drug combination will be also studied.

Sponsored by: M.D. Anderson Cancer Center